The Taiwan-based start-up aims to complete a round of fundraising and a clinical study on lung cancer by the end of the year, said CEO Philip Huang.
“Currently, we have received commitment from just over half the target of our next round of fundraising,” Huang said in an interview on Tuesday, without divulging…
Article Source
https://www.scmp.com/news/china-future-tech/biomedicine/article/3309012/pharus-ai-powered-cancer-test-developer-backed-li-ka-shing-taps-hong-kong-funds